TY - JOUR T1 - Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02089-2017 VL - 51 IS - 1 SP - 1702089 AU - Caroline E. Broos AU - Monique Wapenaar AU - Caspar W.N. Looman AU - Johannes C.C.M. in ’t Veen AU - Leon M. van den Toorn AU - Maria J. Overbeek AU - Marco J.J.H. Grootenboers AU - Roxane Heller AU - Rémy L. Mostard AU - Linda H.C. Poell AU - Henk C. Hoogsteden AU - Mirjam Kool AU - Marlies S. Wijsenbeek AU - Bernt van den Blink Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/51/1/1702089.abstract N2 - Prednisone is the mainstay of sarcoidosis treatment. However, prednisone treatment optimisation is warranted, since prolonged high-dose prednisone therapy is associated with burdensome and harmful side-effects [1, 2]. Early prednisone dose tapering has the potential to reduce side-effects. Gaining insight in the early treatment response can help to determine when tapering could be initiated. To date, there are no prospective studies that look at early treatment response to prednisone in sarcoidosis by monitoring clinical symptoms and daily patient-administered lung function. Therefore, we initiated a multicentre, prospective and observational study with daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis (Dutch National Trial Register NTR4328; www.trialregister.nl/trialreg).The major treatment effect of prednisone on FVC is reached within 2 to 3 weeks in newly treated sarcoidosis patients http://ow.ly/3A3E30h5ZuTThe authors gratefully acknowledge patients, research nurses, respiratory function technologists and physicians participating in this study from Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia hospital, Amphia hospital, Haaglanden Medical Centre and Zuyderland Medical Center Heerlen (all the Netherlands). The authors thank Mirjam van Manen, Linda de Kleer, Frans Mertens and Hadassa de Raaf (Dept of Pulmonary Medicine, Erasmus MC, Rotterdam, the Netherlands) for technical assistance.The authors contributed as follows. C.E. Broos, M. Wapenaar, J.C.C.M. in 't Veen, L.M. van den Toorn, M.J.J.H. Grootenboers, R. Heller, L.H.C. Poell, H.C. Hoogsteden, M.S. Wijsenbeek and B. van den Blink contributed to the study concept and design. C.E. Broos, M. Wapenaar, J.C.C.M. in 't Veen, L.M. van den Toorn, M.J.J.H. Grootenboers, R. Heller M.J. Overbeek, R.L. Mostard, L.H.C. Poell, H.C. Hoogsteden, M. Kool, M.S. Wijsenbeek and B. van den Blink, patient recruitment and data collection. C.E. Broos, M. Wapenaar, C.W.N. Looman, M.S. Wijsenbeek and B. van den Blink, data analysis and interpretation. C.E. Broos, M. Wapenaar, C.W.N. Looman, M.S. Wijsenbeek and B. van den Blink, manuscript preparation and manuscript drafting. All authors gave final approval on the manuscript.. ER -